Investigational drug · Phase 2
DA-2811-C
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Diabete Mellitus.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 20, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "DA-2811-C"
First trial start
2025
Nov 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DA-2811-C", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diabete Mellitus
Approved drugs for the same conditions: Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "DA-2811-C" as an intervention, largest first.
- Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing BT-1 and BT-2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic ControlPivotal-lookingNot yet recruiting
Dong-A ST Co., Ltd.Industry
NCT07239440 · 288 participants (planned) · Start Nov 2025 · Primary completion Dec 2026
Drug: DA-2811; DA-2811-C · For: Diabete Mellitus
Sites: Seoul, South Korea
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Diabete Mellitus
- DA-2811Phase 21 trial
Dong-A ST Co., Ltd. · Diabete Mellitus
- SPC1001Phase 21 trial
Shin Poong Pharmaceutical Co. Ltd. · Hypertension (HTN), NYHA Class III Heart Failure, NYHA Class IV Heart Failure
- SPC5002Phase 21 trial
Shin Poong Pharmaceutical Co. Ltd. · Hypertension (HTN), NYHA Class III Heart Failure, NYHA Class IV Heart Failure
- SPC5003Phase 21 trial
Shin Poong Pharmaceutical Co. Ltd. · Hypertension (HTN), NYHA Class III Heart Failure, NYHA Class IV Heart Failure
- SPC5004Phase 21 trial
Shin Poong Pharmaceutical Co. Ltd. · Hypertension (HTN), NYHA Class III Heart Failure, NYHA Class IV Heart Failure
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.